Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension

ConclusionsPlasma prolargin levels differentiate PAH patients from controls and the other investigated dyspnoea groups including HF. Its potential in PAH differentiation may be enhanced by inclusion in a multi ‐marker panel. Larger studies are needed to evaluate its discriminative ability of PAH in relation to other dyspnoea aetiologies and its potential role in PAH risk stratification and pathobiology.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research